Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir for prevention of clinically significant CMV infection after allogeneic HSCT
2013-003831-31Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in cytomegalovirus disease (CMV) comparing Letermovir with Placebo (2 arms). Primary endpoint: Proportion of subjects with clinically significant CMV infection through Week 24 post-transplant. Started Feb 2014; status: completed.
02
Drugs
letermovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2013-003831-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003831-31.